Liệu pháp phối hợp cho ung thư phổi tế bào nhỏ giai đoạn giới hạn

Jemal A, Tiwari RC, Murray T, et al.: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8–29. Page NC, Read WL, Tierney RM, et al.: The epidemiology of small cell lung carcinoma [abstract 1216]. Proc Am Soc Clin Oncol 2002, 21:305a. Quero Blanco C, Lopez-Picazo JM, Boan J, et al.: Initial staging of small cell lung cancer patients with 18F FDG-PET and conventional imaging techniques [abstract 2618]. Proc Am Soc Clin Oncol 2003, 22:651. Chute JP, Chen T, Feigal E, et al.: Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999, 17:1794–1801. Turrisi AT, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 1999, 340:265–271. This randomized trial established that twice-daily thoracic radiotherapy, administered concomitant with chemotherapy, improves survival of LD-SCLC patients compared to the once a day schedule. Kosmidis P, Samantas E, Fountzilas G, et al.: Cisplatin/ etoposide versus carboplatin/etoposide and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 1994, 21(Suppl 6):23–30. Glisson B, Scott C, Komaki R, et al.: Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small cell lung carcinoma: Results of Radiation Therapy Oncology Group trial 93-12. J Clin Oncol 2000, 18:2990–2995. Ettinger DS, Seiferheld WF, Abrams RA, et al.: Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients with limited disease (LD) small cell lung cancer (SCLC): preliminary results of RTOG 95-09 [abstract]. Proc Am Soc Clin Oncol 2000, 19:490a. Niell HB, Herndon JE, Miller AA: Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer [abstract 2662]. Proc Am Soc Clin Oncol 2002, 21:293a. Schiller JH, Adak S, Cella D, et al.: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:2114–2122. Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002, 346:85–91. This randomized trial from Japan demonstrated a superiority of cisplatin-irinotecan over cisplatin-etoposide in patients with ED-SCLC. Confirmatory trials are ongoing in the United States. Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992, 327:1618–1624. Murray N, Coy P, Pater JL, et al.: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993, 11:336–344. Choi NC, Herndon J, Rosenman J, et al.: Long-term survival data from CALGB 8837: radiation dose escalation and concurrent chemotherapy in limited-stage small cell lung cancer. Possible radiation dose-survival relationship [abstract 1190]. Proc Am Soc Clin Oncol 2002, 21:298a. Auperin A, Arriagada R, Pignon JP, et al.: Prophylactic crania irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999, 341:476–484. This meta-analysis established the role of PCI in decreasing the incidence of brain metastases and improving survival of patients with LD-SCLC in complete remission after combined modality therapy. Vines EF, Le Pechoux C, Arriagada R: Prophylactic cranial irradiation in small cell lung cancer. Semin Oncol 2003, 30:38–46. Shepherd FA: Surgical management of small cell lung cancer. In Lung Cancer: Principles and Practice. Edited by Pass HI, et al.: Baltimore: Lippincott Williams & Wilkins; 2000:967–980. Lad T, Piantadosi S, Thomas P, et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106(Suppl):320–323. Shepherd F, Giaccone G, Debruyne C, et al.: Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer following response to first-line chemotherapy: An NCIC and EORTC study [abstract]. Pro Am Soc Clin Oncol 2001, 20:1. Johnson BE, Fisher B, Fisher T, et al.: Phase II study of STI571 (Gleevec) for patients with small cell lung cancer [abstract 1171]. Proc Am Soc Clin Oncol 2002, 21:293a. Grant SC, Kris MG, Houghton AN, et al.: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999, 5:1319–1323. Giaccone G, Debruyne C, Felip E, et al.: Phase III study of BEC/BCG vaccination in limited disease small cell lung cancer patients following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study) [abstract 7020]. Proc Am Soc Clin Oncol 2004, 18. This randomized trial failed to demonstrate a survival benefit for vaccination with BEC/BCG in patients with LD-SCLC.